In glioblastoma patients, while cabozantinib (XL184), a non-selective, ATP competitor targeting MET, VEGFR2, and AXL demonstrated encouraging clinical efficacy in a phase II trial in glioblastoma (GBM) [19–21], rilotumumab, an HGF antibody, showed a lack of efficacy, possibly due to the selection of patients who were heavily pretreated by other therapeutics [22]. Here, AXL is linked to glioblastoma.